{"id":2759,"date":"2026-03-31T21:02:02","date_gmt":"2026-03-31T19:02:02","guid":{"rendered":"https:\/\/vip2-msd.com\/switzerland\/?page_id=2759"},"modified":"2026-03-31T21:02:15","modified_gmt":"2026-03-31T19:02:15","slug":"clinical-trials-in-switzerland","status":"publish","type":"page","link":"https:\/\/www.msd.ch\/de\/home\/research\/clinical-trials\/clinical-trials-in-switzerland\/","title":{"rendered":"Klinische Studien von MSD in der Schweiz"},"content":{"rendered":"\n<div id=\"mco-b2-hero-block-block_8d1a50aea206130af7a7aa948f4f4e85\" class=\"mco-b2-hero-block full mccberg-block\">\n    <div class=\"mco-b2-hero-block-wrapper\">\n        <div class=\"mco-b2-hero-block-image-section \">\n\n                            <div class=\"mco-b2-hero-block-image-container \">\n                    <picture >\n\t<source media=\"(max-width: 767px)\" data-srcset=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2021\/06\/portrait_klaudia_georgi.jpg?w=768\" srcset=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2021\/06\/portrait_klaudia_georgi.jpg?w=768\" >\n<source media=\"(min-width: 768px) and (max-width: 1199px)\" data-srcset=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2021\/06\/portrait_klaudia_georgi.jpg?h=768\" srcset=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2021\/06\/portrait_klaudia_georgi.jpg?h=768\" >\n<source media=\"(min-width: 1200px) and (max-width: 1919px)\" data-srcset=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2021\/06\/portrait_klaudia_georgi.jpg?w=1200\" srcset=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2021\/06\/portrait_klaudia_georgi.jpg?w=1200\" >\n<source media=\"(min-width: 1920px)\" data-srcset=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2021\/06\/portrait_klaudia_georgi.jpg?w=1920\" srcset=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2021\/06\/portrait_klaudia_georgi.jpg?w=1920\" >\n\t<img data-src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2021\/06\/portrait_klaudia_georgi.jpg?w=1920\" alt=\"\" class=\"eager \" loading=\"eager\" \/>\n<\/picture>                                    <\/div>\n                        <div class=\"mco-b2-hero-block-image-container-two\">\n                            <\/div>\n        <\/div>\n\n        <div class=\"mco-b2-hero-block-content-section\">\n            <nav class=\"breadcrumbs wrapper text-descriptive\"aria-label=\"Breadcrumbs\"><\/nav>            \n                            <h1>Klinische Studien von MSD in der Schweiz<\/h1>\n            \n                            <div class=\"mco-b2-hero-block-description\"><p>\u201cKlinische Studien sind der Schl\u00fcssel zu neuen Erkenntnissen in der Diagnostik und Therapie von Erkrankungen. Wir sind stolz, in der Schweiz dazu beizutragen.&#8221;<\/p>\n<p><em>Klaudia Georgi, Sr. Director Clinical Research MSD Switzerland &amp; Serbia<\/em><\/p>\n<\/div>\n            \n                            <a class=\"btn\" href=\"https:\/\/www.msd.ch\/de\/home\/research\/clinical-trials\/\"\n                   title=\"Grundwissen Klinische Studien\"\n                   target=\"_self\"\n                                   >Grundwissen Klinische Studien<\/a>\n                    <\/div>\n    <\/div>\n\n    \n<\/div>\n\n\n<div id=\"mco-title-block-block_263aeda1db8c761c2c6389333d153618\" \n\t class=\"mco-title-block mccberg-block pull-up-stats negative mb-2 aligncenter\" \n\t \t >\n\t<div class=\"wrapper\">\n\t\t<div class=\"mco-title-block-content\">\n\t\t\t\n\t\t\t<h2 class=\"mco-title-block-title\">Unsere Arbeit in Zahlen<\/h2>\n\n\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n<div class=\"wp-block-group\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><div id=\"stat-block-block_dca6e411a58d3ae1d09bdd7fa6dcb756\" class=\"stat-block mccberg-block\">\n    <div class=\"stat-block-content  \">\n\n        \n        <div class=\"stat-block-statistic\">40<\/div>\n\n        <div class=\"stat-block-tablet-wrapper\">\n                        <p class=\"stat-block-description\">Laufende klinische Studien in der Schweiz\r\n(Stand 01\/2026)\r\n<\/p>\n            \n                    <\/div>\n\n    <\/div>\n<\/div>\n\n<div id=\"stat-block-block_0b1aa1f25a359dfb36960543edbecd57\" class=\"stat-block mccberg-block\">\n    <div class=\"stat-block-content  \">\n\n        \n        <div class=\"stat-block-statistic\">10<\/div>\n\n        <div class=\"stat-block-tablet-wrapper\">\n                        <p class=\"stat-block-description\">In der Schweiz zugelassene First-in-Class-Medikamente und Impfstoffe seit 2000\r\n(Stand 01\/2026)<\/p>\n            \n                    <\/div>\n\n    <\/div>\n<\/div>\n\n<div id=\"stat-block-block_b9271fb59c7fc72202dc5d37676f5fc9\" class=\"stat-block mccberg-block\">\n    <div class=\"stat-block-content  \">\n\n        \n        <div class=\"stat-block-statistic\">173<\/div>\n\n        <div class=\"stat-block-tablet-wrapper\">\n                        <p class=\"stat-block-description\">Millionen Schweizer Franken in die Forschung investiert, seit 2012 \r\n(Stand 01\/2026)<\/p>\n            \n                    <\/div>\n\n    <\/div>\n<\/div><\/div><\/div>\n\n\n<div id=\"mco-b5-content-block-block_9ca5df0ac12faa5cecf576f1bdcb5682\"\n     class=\"mco-b5-content-block mccberg-block left\">\n    <div class=\"wrapper\">\n\t\t\t\t\t\t\t            <div class=\"mco-b5-content-block-image-section \">\n\t\t\t\t                <picture aria-label=\"MSD-Niederlassung R\u00f6sslimatt in Luzern\">\n                                                                        <source media=\"(max-width: 767px)\"\n                                    data-srcset=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2026\/03\/Picture-Rosslimatt.jpg?resize=696,425\" \/>\n                                                                                                <source media=\"(min-width: 768px) and (max-width: 1199px)\"\n                                    data-srcset=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2026\/03\/Picture-Rosslimatt.jpg?resize=384,468\" \/>\n                                                                                                <source media=\"(min-width: 1200px)\"\n                                    data-srcset=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2026\/03\/Picture-Rosslimatt.jpg?resize=750,650\" \/>\n                                                                                                <source media=\"(min-width: 1600px)\"\n                                    data-srcset=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2026\/03\/Picture-Rosslimatt.jpg?resize=850,744\" \/>\n                                                                                                <source media=\"(min-width: 1920px)\"\n                                    data-srcset=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2026\/03\/Picture-Rosslimatt.jpg?resize=980,832\" \/>\n                                                                                                <img\n                                data-src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2026\/03\/Picture-Rosslimatt.jpg?resize=650,544\"\n                                alt=\"MSD-Niederlassung R\u00f6sslimatt in Luzern\"\n                                class=\"lazyload parallax-scroll\"\n                                loading=\"lazy\"\n                            \/>\n                                                            <\/picture>\n\t\t\t\t            <\/div>\n\t\t        <div class=\"mco-b5-content-block-content-section\">\n\t\t\t\n\t\t\t                <h3 class=\"mco-b5-content-block-heading mcc-b5-normal-title\">\n                    Die klinische Forschung von MSD Schweiz wird in unserer Niederlassung in der R\u00f6sslimatt in Luzern koordiniert.                <\/h3 >\n\t\t\t\n\t\t\t\n                        <div class=\"mco-b5-content-block-content-buttons-container\">\n\t\t\t\t                    <a class=\"btn secondary read_more\"\n                       href=\"https:\/\/www.msd.ch\/de\/home\/about-us\/sites\/\"\n                       title=\"Unsere Niederlassungen\"\n                                              target=\"_blank\">Unsere Niederlassungen<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t            <\/div>\n        <\/div>\n    <\/div>\n<\/div>\n<div class=\"mco-b5-content-block-modal popup\" style=\"display: none;\" role=\"dialog\" >\n    <div class=\"popup-wrapper\">\n        <div class=\"mco-b5-content-block-modal-content popup-content\">\n            <button class=\"mco-b5-content-block-modal-close popup-close\" >&times;<\/button>\n            <div class=\"mco-b5-content-block-modal-video\"><\/div>\n        <\/div>\n    <\/div>\n<\/div>\n\n\n\n<h1 class=\"wp-block-heading has-text-align-center\">Das klinische Studienprogramm von MSD in der Schweiz (Stand 01\/2026)<\/h1>\n\n\n\n<p class=\"has-text-align-center\">(ver\u00f6ffentlicht auf <a href=\"http:\/\/www.clinicaltrials.gov\">www.clinicaltrials.gov<\/a>)<\/p>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full mb-2\"><img loading=\"lazy\" decoding=\"async\" width=\"2500\" height=\"1150\" src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2026\/01\/2026-01-MSD-Karte-Klinische-Studienprogramm-Schweiz.png\" alt=\"Karte: Standorte Klinische Studie MSD Schweiz (Stand 01\/2026)\" class=\"wp-image-13485\"\/><\/figure>\n<\/div>\n<\/div>\n\n\n\n<div data-type=\"multiple\" itemscope itemtype=\"https:\/\/schema.org\/FAQPage\" id=\"accordion_list_block_906e1e698ad2b9a2e1838143c7290ccf\" class=\"b6-accordion-list mccberg-block\">\n    \n    <div class=\"b6-accordion-list-block-heading\">\n        <h2>\n            <span>Im Bereich Allgemeinmedizin<\/span>\n        <\/h2>\n                    <button\n                class=\"btn tertiary b6-accordion-list-toggle-expand\"\n                data-open-text=\"Alle aufklappen\"\n                data-close-text=\"Alle schliessen\"\n                aria-label=\"Alle aufklappen\"\n            >\n                <span class=\"open-text\">Alle aufklappen<\/span>\n                <span class=\"close-text\">Alle schliessen<\/span>\n            <\/button>\n            <\/div>\n\n                        <div itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\" class=\"b6-accordion-list-item\">\n                <details  id=\"mcc_details_id_1\" class=\"b6-accordion-list-item-details\">\n                    <summary itemprop=\"name\"  class=\"b6-accordion-list-item-summary\">\n                        <h5 class= 'b6-accordion-list-item-summary-heading'>Lungenkrankheit<\/h5>                    <\/summary>\n                    <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\"  class=\"b6-accordion-list-item-content\">\n                        <div itemprop=\"text\" ><p><strong>MK-5475-013 \u2013 recruitment closed<\/strong><\/p>\n<p>A Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease<\/p>\n<p>Study centers: St. Gallen, Zurich, Basel<\/p>\n<p>&nbsp;<\/p>\n<p><strong>MK-7962-038 \u2013 Study in start-up<\/strong><\/p>\n<p>An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH<\/p>\n<p>Study center: Zurich<\/p>\n<\/div>\n                                            <\/div>\n                <\/details>\n                <hr \/>\n            <\/div>\n            <\/div>\n\n\n<div data-type=\"multiple\" itemscope itemtype=\"https:\/\/schema.org\/FAQPage\" id=\"accordion_list_block_47e1faf69de0af083e4da5e465f4532f\" class=\"b6-accordion-list mccberg-block\">\n    \n    <div class=\"b6-accordion-list-block-heading\">\n        <h2>\n            <span>Im Bereich Immunologie<\/span>\n        <\/h2>\n                    <button\n                class=\"btn tertiary b6-accordion-list-toggle-expand\"\n                data-open-text=\"Alle aufklappen\"\n                data-close-text=\"Alle schliessen\"\n                aria-label=\"Alle aufklappen\"\n            >\n                <span class=\"open-text\">Alle aufklappen<\/span>\n                <span class=\"close-text\">Alle schliessen<\/span>\n            <\/button>\n            <\/div>\n\n                        <div itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\" class=\"b6-accordion-list-item\">\n                <details  id=\"mcc_details_id_1\" class=\"b6-accordion-list-item-details\">\n                    <summary itemprop=\"name\"  class=\"b6-accordion-list-item-summary\">\n                        <h5 class= 'b6-accordion-list-item-summary-heading'>Darmkrankheit<\/h5>                    <\/summary>\n                    <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\"  class=\"b6-accordion-list-item-content\">\n                        <div itemprop=\"text\" ><p><strong>MK-7240-001 \u2013 recruitment closed<\/strong><\/p>\n<p>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Ulcerative Colitis<\/p>\n<p>Study centers: Bern, St. Gallen, Zurich<\/p>\n<p>&nbsp;<\/p>\n<p><strong>MK-7240-008 \u2013 recruitment open<\/strong><\/p>\n<p>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Crohn\u2019s Disease<\/p>\n<p>Study centers: Basel, Bern, St. Gallen, Zurich<\/p>\n<\/div>\n                                            <\/div>\n                <\/details>\n                <hr \/>\n            <\/div>\n            <\/div>\n\n\n<div data-type=\"multiple\" itemscope itemtype=\"https:\/\/schema.org\/FAQPage\" id=\"accordion_list_block_78c3d8fc05dfda4fac3a3bf677819f1f\" class=\"b6-accordion-list mccberg-block mt-2\">\n    \n    <div class=\"b6-accordion-list-block-heading\">\n        <h2>\n            <span>Im Bereich Infektiologie<\/span>\n        <\/h2>\n                    <button\n                class=\"btn tertiary b6-accordion-list-toggle-expand\"\n                data-open-text=\"Alle aufklappen\"\n                data-close-text=\"Alle schliessen\"\n                aria-label=\"Alle aufklappen\"\n            >\n                <span class=\"open-text\">Alle aufklappen<\/span>\n                <span class=\"close-text\">Alle schliessen<\/span>\n            <\/button>\n            <\/div>\n\n                        <div itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\" class=\"b6-accordion-list-item\">\n                <details  id=\"mcc_details_id_1\" class=\"b6-accordion-list-item-details\">\n                    <summary itemprop=\"name\"  class=\"b6-accordion-list-item-summary\">\n                        <h5 class= 'b6-accordion-list-item-summary-heading'>HIV<\/h5>                    <\/summary>\n                    <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\"  class=\"b6-accordion-list-item-content\">\n                        <div itemprop=\"text\" ><div class=\"col s12\">\n<div class=\"col s12\">\n<div class=\"col s12\">\n<div class=\"col s12\">\n<p><strong>MK-8527-011 \u2013 recruitment open<\/strong><\/p>\n<p>Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis<\/p>\n<p>Study centers: Basel, Bern, Zurich<\/p>\n<p>&nbsp;<\/p>\n<p><strong>MK-8591A-051 \u2013 recruitment closed<\/strong><\/p>\n<\/div>\n<p>A Phase 3, Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine\/Islatravir (DOR\/ISL 100 mg\/0.25 mg) Once-Daily in Participants With HIV-1 Who Are Virologically Suppressed on Antiretroviral Therapy<\/p>\n<p>Study centers: Basel, Bern, Geneva, Lausanne, Lugano, Zurich<\/p>\n<p>&nbsp;<\/p>\n<\/div>\n<p><strong>MK-8591A-053 \u2013 recruitment closed<\/strong><\/p>\n<p>A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine\/Islatravir (DOR\/ISL 100 mg\/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Na\u00efve Participants<\/p>\n<p>Study centers: Basel, Geneva<\/p>\n<p>&nbsp;<\/p>\n<div class=\"col s12\">\n<p><strong>MK-8591A-054 \u2013 recruitment closed<\/strong><\/p>\n<p>A Phase 3 Open-label Clinical Study of Doravirine\/Islatravir (DOR\/ISL [100 mg\/0.25 mg]) Once Daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR\/ISL (100 mg\/0.75 mg) QD in a Phase 3 Clinical Study<\/p>\n<p>Study centers: Basel, Bern, Geneva, St. Gallen, Lugano, Zurich<\/p>\n<p>&nbsp;<\/p>\n<\/div>\n<p><strong>MK-8591B-060 \u2013 recruitment closed<\/strong><\/p>\n<p>A Phase 2b, Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Islatravir (ISL) and Ulonivirine (ULO) Once-Weekly in Adults with HIV-1 Virologically Suppressed on Bictegravir\/Emtricitabine\/Tenofovir Alafenamide (BIC\/FTC\/TAF) Once-Daily<\/p>\n<p>Study centers: Basel, Bern, Geneva, Lugano<\/p>\n<\/div>\n<\/div>\n<\/div>\n                                            <\/div>\n                <\/details>\n                <hr \/>\n            <\/div>\n            <\/div>\n\n\n<div data-type=\"multiple\" itemscope itemtype=\"https:\/\/schema.org\/FAQPage\" id=\"accordion_list_block_30086c0364fe769344301becb2566c4e\" class=\"b6-accordion-list mccberg-block\">\n    \n    <div class=\"b6-accordion-list-block-heading\">\n        <h2>\n            <span>Im Bereich Onkologie<\/span>\n        <\/h2>\n                    <button\n                class=\"btn tertiary b6-accordion-list-toggle-expand\"\n                data-open-text=\"Alle aufklappen\"\n                data-close-text=\"Alle schliessen\"\n                aria-label=\"Alle aufklappen\"\n            >\n                <span class=\"open-text\">Alle aufklappen<\/span>\n                <span class=\"close-text\">Alle schliessen<\/span>\n            <\/button>\n            <\/div>\n\n                        <div itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\" class=\"b6-accordion-list-item\">\n                <details  id=\"mcc_details_id_1\" class=\"b6-accordion-list-item-details\">\n                    <summary itemprop=\"name\"  class=\"b6-accordion-list-item-summary\">\n                        <h5 class= 'b6-accordion-list-item-summary-heading'>Blasenkrebs<\/h5>                    <\/summary>\n                    <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\"  class=\"b6-accordion-list-item-content\">\n                        <div itemprop=\"text\" ><p class=\"col l9 m9 s12\"><strong>MK-3475-676\/KEYNOTE-676 &#8211; recruitment closed<\/strong><\/p>\n<p class=\"col l9 m9 s12\">A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HRNMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)<\/p>\n<p class=\"col l2 m2 offset-l1 offset-m1 s12\">Study centers: Basel, Geneva, Zurich<\/p>\n<\/div>\n                                            <\/div>\n                <\/details>\n                <hr \/>\n            <\/div>\n                    <div itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\" class=\"b6-accordion-list-item\">\n                <details  id=\"mcc_details_id_2\" class=\"b6-accordion-list-item-details\">\n                    <summary itemprop=\"name\"  class=\"b6-accordion-list-item-summary\">\n                        <h5 class= 'b6-accordion-list-item-summary-heading'>Blutkrebs (H\u00e4matologische Malignome)<\/h5>                    <\/summary>\n                    <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\"  class=\"b6-accordion-list-item-content\">\n                        <div itemprop=\"text\" ><p><strong>MK-1026-003 &#8211; recruitment open<\/strong><\/p>\n<p>A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies<\/p>\n<p>Study centers: Bellinzona, Bern<\/p>\n<p>&nbsp;<\/p>\n<p><strong>MK-2140-010 \u2013 recruitment open<\/strong><\/p>\n<p>A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)<\/p>\n<p>Study centers: Baden, Bellinzona, St. Gallen<\/p>\n<p>&nbsp;<\/p>\n<p><strong>MK-4280A-008 \u2013 recruitment closed<\/strong><\/p>\n<p>A Phase 3 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician\u2019s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)<\/p>\n<p>Study centers: Bellinzona<\/p>\n<\/div>\n                                            <\/div>\n                <\/details>\n                <hr \/>\n            <\/div>\n                    <div itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\" class=\"b6-accordion-list-item\">\n                <details  id=\"mcc_details_id_3\" class=\"b6-accordion-list-item-details\">\n                    <summary itemprop=\"name\"  class=\"b6-accordion-list-item-summary\">\n                        <h5 class= 'b6-accordion-list-item-summary-heading'>Brustkrebs<\/h5>                    <\/summary>\n                    <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\"  class=\"b6-accordion-list-item-content\">\n                        <div itemprop=\"text\" ><p><strong>MK-2870-010 \u2013 recruitment open<\/strong><\/p>\n<p>An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician`s Choice in Participants with HR+\/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer<\/p>\n<p>Study centers: Basel, Thun, Zurich<\/p>\n<p>&nbsp;<\/p>\n<p><strong>MK-2870-012 \u2013 recruitment open<\/strong><\/p>\n<p>A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician\u2019s Choice in Participants With Triple Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) At Surgery<\/p>\n<p>Study centers: Chur, Fribourg, Geneva, Thun, Zurich<\/p>\n<\/div>\n                                            <\/div>\n                <\/details>\n                <hr \/>\n            <\/div>\n                    <div itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\" class=\"b6-accordion-list-item\">\n                <details  id=\"mcc_details_id_4\" class=\"b6-accordion-list-item-details\">\n                    <summary itemprop=\"name\"  class=\"b6-accordion-list-item-summary\">\n                        <h5 class= 'b6-accordion-list-item-summary-heading'>Gyn\u00e4kologische Krebserkrankungen<\/h5>                    <\/summary>\n                    <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\"  class=\"b6-accordion-list-item-content\">\n                        <div itemprop=\"text\" ><p><strong>MK-2870-005 \u2013 recruitment closed<\/strong><\/p>\n<p>A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician\u2019s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy<\/p>\n<p>Study centers: Bern, Bellinzona, Chur, Basel<\/p>\n<p>&nbsp;<\/p>\n<p><strong>MK-2870-020 \u2013 recruitment closed<\/strong><\/p>\n<p>A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician\u2019s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer<\/p>\n<p>Study centers: Basel, Bern<\/p>\n<p>&nbsp;<\/p>\n<p><strong>MK-2870-021 \u2013 Study in start-up<\/strong><\/p>\n<p>A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021\/ENGOTov85\/GOG-3102)<\/p>\n<p>Study centers: Bern, Bellinzona, Chur, Geneva, Winterthur<\/p>\n<\/div>\n                                            <\/div>\n                <\/details>\n                <hr \/>\n            <\/div>\n                    <div itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\" class=\"b6-accordion-list-item\">\n                <details  id=\"mcc_details_id_5\" class=\"b6-accordion-list-item-details\">\n                    <summary itemprop=\"name\"  class=\"b6-accordion-list-item-summary\">\n                        <h5 class= 'b6-accordion-list-item-summary-heading'>Kopf- und Halskrebs<\/h5>                    <\/summary>\n                    <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\"  class=\"b6-accordion-list-item-content\">\n                        <div itemprop=\"text\" ><div class=\"col s12\">\n<div class=\"col s12\"><strong>MK-3475-689\/KEYNOTE-689 \u2013 recruitment closed<\/strong><\/div>\n<div class=\"col s12\">\n<p>A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)<\/p>\n<p>Study center: Geneva<\/p>\n<\/div>\n<\/div>\n<\/div>\n                                            <\/div>\n                <\/details>\n                <hr \/>\n            <\/div>\n                    <div itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\" class=\"b6-accordion-list-item\">\n                <details  id=\"mcc_details_id_6\" class=\"b6-accordion-list-item-details\">\n                    <summary itemprop=\"name\"  class=\"b6-accordion-list-item-summary\">\n                        <h5 class= 'b6-accordion-list-item-summary-heading'>Lungenkrebs<\/h5>                    <\/summary>\n                    <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\"  class=\"b6-accordion-list-item-content\">\n                        <div itemprop=\"text\" ><p><strong>MK-1084-007 \u2013 Study in start-up<\/strong><\/p>\n<p>A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed\/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)<\/p>\n<p>Study centers: Fribourg, Zurich<\/p>\n<p>&nbsp;<\/p>\n<p><strong>MK-2870-019 \u2013 <span class=\"gray_text\">recruitment open<\/span><\/strong><\/p>\n<p>A Phase 3 Randomized Open-label Study of Adjuvant Pembrolizumab with or without MK-2870 in Resectable Stages II-IIIB (N2) NSCLC for participants not achieving pCR after Receiving Neoadjuvant Pembrolizumab with Platinum-based Doublet Chemotherapy Followed by Surgery<\/p>\n<p>Study centers: Lausanne, Fribourg, Frauenfeld, Chur<\/p>\n<p>&nbsp;<\/p>\n<div class=\"col s12\">\n<p class=\"col l9 m9 s12\"><strong>MK-3475-091\/KEYNOTE-091 &#8211;\u00a0<span class=\"gray_text\">outsourced &#8211; recruitment closed<\/span><\/strong><\/p>\n<p class=\"col l9 m9 s12\">A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)<\/p>\n<p class=\"col l2 m2 offset-l1 offset-m1 s12\">Study centers: Basel, Bellinzona, Bern, Chur, Geneva, Lausanne, Lucerne, St. Gallen, Winterthur, Zurich<\/p>\n<p>&nbsp;<\/p>\n<\/div>\n<div class=\"col s12\">\n<p><strong>MK-3475-B98 &#8211; recruitment closed<\/strong><\/p>\n<\/div>\n<div class=\"col s12\">\n<p class=\"col l9 m9 s12\">A Phase 1b\/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1\/L1-refactory Extensive Stage Small Cell Lung Cancer in Need of Second-Line Therapy<\/p>\n<p class=\"col l2 m2 offset-l1 offset-m1 s12\">Study center: St. Gallen<\/p>\n<\/div>\n<\/div>\n                                            <\/div>\n                <\/details>\n                <hr \/>\n            <\/div>\n                    <div itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\" class=\"b6-accordion-list-item\">\n                <details  id=\"mcc_details_id_7\" class=\"b6-accordion-list-item-details\">\n                    <summary itemprop=\"name\"  class=\"b6-accordion-list-item-summary\">\n                        <h5 class= 'b6-accordion-list-item-summary-heading'>Magenkrebs<\/h5>                    <\/summary>\n                    <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\"  class=\"b6-accordion-list-item-content\">\n                        <div itemprop=\"text\" ><div class=\"col s12\">\n<div class=\"col s12\">\n<div class=\"col s12\">\n<p><strong>MK-1022-011 \u2013 recruitment open<\/strong><\/p>\n<p>A Phase 1\/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers<\/p>\n<p>Study centers: Geneva, Zurich<\/p>\n<p>&nbsp;<\/p>\n<\/div>\n<div class=\"col s12\">\n<p class=\"col l2 m2 offset-l1 offset-m1 s12\"><strong>MK-5909-005 \u2013 recruitment open<\/strong><\/p>\n<\/div>\n<p>A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers<\/p>\n<p>Study centers: Basel, Zurich, Geneva<\/p>\n<p>&nbsp;<\/p>\n<p><strong>MK-9999-U02A \u2013 recruitment open<\/strong><\/p>\n<p>A Phase 1\/2 Substudy of the MK-9999-U02 Master Protocol to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers<\/p>\n<p>Study centers: Bellinzona, Geneva<\/p>\n<\/div>\n<\/div>\n<\/div>\n                                            <\/div>\n                <\/details>\n                <hr \/>\n            <\/div>\n                    <div itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\" class=\"b6-accordion-list-item\">\n                <details  id=\"mcc_details_id_8\" class=\"b6-accordion-list-item-details\">\n                    <summary itemprop=\"name\"  class=\"b6-accordion-list-item-summary\">\n                        <h5 class= 'b6-accordion-list-item-summary-heading'>Melanom (Schwarzer Hautkrebs)<\/h5>                    <\/summary>\n                    <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\"  class=\"b6-accordion-list-item-content\">\n                        <div itemprop=\"text\" ><div class=\"col s12\">\n<div class=\"col s12\"><strong>MK-3475-054 \/ KEYNOTE-054 &#8211; <span class=\"gray_text\">outsourced &#8211; recruitment closed<\/span><\/strong><\/div>\n<div class=\"col s12\">\n<p class=\"col l9 m9 s12\">Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group<\/p>\n<p class=\"col l2 m2 offset-l1 offset-m1 s12\">Study centers: Geneva, Zurich<\/p>\n<p>&nbsp;<\/p>\n<\/div>\n<div class=\"col s12\">\n<p class=\"col l9 m9 s12\"><strong>MK-3475-716\/KEYNOTE-716 &#8211;\u00a0<span class=\"green_text\">recruitment closed<\/span><\/strong><\/p>\n<p class=\"col l9 m9 s12\">Adjuvant Therapy with Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study<\/p>\n<p class=\"col l2 m2 offset-l1 offset-m1 s12\">Study centers: Bellinzona, Bern, Chur, Geneva, Lausanne, Sion, St. Gallen, Zurich<\/p>\n<\/div>\n<\/div>\n<\/div>\n                                            <\/div>\n                <\/details>\n                <hr \/>\n            <\/div>\n                    <div itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\" class=\"b6-accordion-list-item\">\n                <details  id=\"mcc_details_id_9\" class=\"b6-accordion-list-item-details\">\n                    <summary itemprop=\"name\"  class=\"b6-accordion-list-item-summary\">\n                        <h5 class= 'b6-accordion-list-item-summary-heading'>Nierenkrebs (Nierenzellkarzinom)<\/h5>                    <\/summary>\n                    <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\"  class=\"b6-accordion-list-item-content\">\n                        <div itemprop=\"text\" ><p class=\"col l9 m9 s12\"><strong>MK-6482-011 &#8211; recruitment closed<\/strong><\/p>\n<p class=\"col l9 m9 s12\">An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1\/L1 Therapy<\/p>\n<p class=\"col l2 m2 offset-l1 offset-m1 s12\">Study centers: Bellinzona, Chur, Geneva, Zurich<\/p>\n<\/div>\n                                            <\/div>\n                <\/details>\n                <hr \/>\n            <\/div>\n                    <div itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\" class=\"b6-accordion-list-item\">\n                <details  id=\"mcc_details_id_10\" class=\"b6-accordion-list-item-details\">\n                    <summary itemprop=\"name\"  class=\"b6-accordion-list-item-summary\">\n                        <h5 class= 'b6-accordion-list-item-summary-heading'>Prostatakrebs<\/h5>                    <\/summary>\n                    <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\"  class=\"b6-accordion-list-item-content\">\n                        <div itemprop=\"text\" ><p><strong>MK-2400-001 \u2013 recruitment open<\/strong><\/p>\n<p>A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)<\/p>\n<p>Study centers: Aarau, Basel, Fribourg, Geneva, Zurich<\/p>\n<\/div>\n                                            <\/div>\n                <\/details>\n                <hr \/>\n            <\/div>\n                    <div itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\" class=\"b6-accordion-list-item\">\n                <details  id=\"mcc_details_id_11\" class=\"b6-accordion-list-item-details\">\n                    <summary itemprop=\"name\"  class=\"b6-accordion-list-item-summary\">\n                        <h5 class= 'b6-accordion-list-item-summary-heading'>Solide Tumore<\/h5>                    <\/summary>\n                    <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\"  class=\"b6-accordion-list-item-content\">\n                        <div itemprop=\"text\" ><div class=\"col s12\">\n<div class=\"col s12\">\n<div class=\"col s12\">\n<div class=\"col s12\">\n<p><strong>MK-0472-001 \u2013 recruitment open<\/strong><\/p>\n<p>A Phase 1\/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants with Advanced\/Metastatic Solid Tumors.<\/p>\n<p>Study centers: Geneva, Bellinzona, St. Gallen<\/p>\n<p>&nbsp;<\/p>\n<p class=\"col l9 m9 s12\"><strong>MK-1084-001 &#8211; recruitment open<\/strong><\/p>\n<p>A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors<\/p>\n<p>Study centers: Bellinzona, St. Gallen<\/p>\n<\/div>\n<\/div>\n<p>&nbsp;<\/p>\n<p class=\"col l9 m9 s12\"><strong>MK-3475-587\/KEYNOTE-587 &#8211; recruitment closed<\/strong><\/p>\n<p class=\"col l9 m9 s12\">Long-term Safety and Efficacy Extension Study for Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study<\/p>\n<p class=\"col l2 m2 offset-l1 offset-m1 s12\">Study center: Basel, Geneva, Zurich<\/p>\n<p>&nbsp;<\/p>\n<p><strong>MK-4884-001 \u2013 Study in start-up<\/strong><\/p>\n<p>A Phase 1 Open-label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-4884 in Participants with Advanced Solid Tumors<\/p>\n<p>Study centers: Bellinzona, Lausanne, St. Gallen<\/p>\n<p>&nbsp;<\/p>\n<div class=\"col s12\">\n<p><strong>MK-7339-002 &#8211; recruitment closed<\/strong><\/p>\n<\/div>\n<div class=\"col s12\">\n<p class=\"col l9 m9 s12\">A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer<\/p>\n<p class=\"col l2 m2 offset-l1 offset-m1 s12\">Study center: Bellinzona<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n                                            <\/div>\n                <\/details>\n                <hr \/>\n            <\/div>\n                    <div itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\" class=\"b6-accordion-list-item\">\n                <details  id=\"mcc_details_id_12\" class=\"b6-accordion-list-item-details\">\n                    <summary itemprop=\"name\"  class=\"b6-accordion-list-item-summary\">\n                        <h5 class= 'b6-accordion-list-item-summary-heading'>Speiser\u00f6hrenkrebs<\/h5>                    <\/summary>\n                    <div itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\"  class=\"b6-accordion-list-item-content\">\n                        <div itemprop=\"text\" ><p><strong>MK-3475-06B \u2013 recruitment open<\/strong><\/p>\n<p>A Phase 1\/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1\/PD-L1 Treatment: Substudy 06B.<\/p>\n<p>Study centers: Chur, Geneva<\/p>\n<p>&nbsp;<\/p>\n<p><strong>MK-3475-06C \u2013 recruitment open<\/strong><\/p>\n<p>A Phase 1\/2 Open-Label, Umbrella Platform Design Study of MK-2870 With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable\/ Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma): Substudy 06C<\/p>\n<p>Study centers: Chur, Geneva<\/p>\n<p>&nbsp;<\/p>\n<p><strong>MK-3475-06D \u2013 recruitment open<\/strong><\/p>\n<p>A Phase 1\/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of MK-2870 Plus Paclitaxel as the Second-Line Treatment of Participants With Advanced\/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D<\/p>\n<p>Study centers: Chur, Geneva<\/p>\n<p>&nbsp;<\/p>\n<p><strong>MK-3475-06E \u2013 recruitment open<\/strong><\/p>\n<p>A Phase 1\/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable\/Metastatic Esophageal Cancer: Substudy 06E<\/p>\n<p>Study centers: Chur, Geneva<\/p>\n<p>&nbsp;<\/p>\n<p><strong>MK-3475-06F \u2013 Study in start-up <\/strong><\/p>\n<p>A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L\/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: Substudy 06F<\/p>\n<p>Study centers: Chur, Geneva<\/p>\n<\/div>\n                                            <\/div>\n                <\/details>\n                <hr \/>\n            <\/div>\n            <\/div>\n\n\n<p>Zur \u00dcbersicht der schweizweiten Studien, die Teilnehmende suchen, <a href=\"https:\/\/www.humanforschung-schweiz.ch\/de\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">www.humanforschung-schweiz.ch<\/a><\/p>\n\n\n<div id=\"mco-featured-banner-block-block_44f0f3e9f33a227d8e146c133c2d4f12\" class=\"mco-featured-banner-block full mccberg-block negative\">\n\n\n            <div class=\"mco-featured-banner-image-container\">\n            <picture>\n                <source media=\"(max-width: 767px)\" data-srcset=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2021\/06\/research_oncology.jpg?resize=767,956\">\n                <source media=\"(min-width: 768px) and (max-width: 1199px)\" data-srcset=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2021\/06\/research_oncology.jpg?resize=768,448\">\n                <source media=\"(min-width: 1200px)\" data-srcset=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2021\/06\/research_oncology.jpg?w=1600\">\n                <img data-src=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2021\/06\/research_oncology.jpg?w=1600\" alt=\"Featured banner image\" class=\"lazyload\" loading=\"lazy\" \/>\n            <\/picture>\n        <\/div>\n    \n\n    <div class=\"mco-featured-banner-content-container\">\n        <div class=\"mco-featured-banner-content-card\">\n            \n                            <h3>Wir m\u00f6chten Menschen mit Krebs Hoffnung schenken<\/h3>\n            \n                            <div><p>Wir investieren in die Entwicklung innovativer onkologischer Medikamente, um Menschen mit Krebserkrankungen zu helfen.<\/p>\n<\/div>\n            \n            <div class=\"mco-featured-banner-btn-container\">\n                                    <a class=\"btn\"\n                       href=\"https:\/\/www.msd.ch\/de\/about-msd\/areas-of-focus\/oncology\/\"\n                       title=\"Mehr erfahren\"\n                       target=\"_blank\"\n                                           >Mehr erfahren<\/a>\n                \n                            <\/div>\n        <\/div>\n    <\/div>\n<\/div>\n\n\n\n<p><sup>CH-NON-00136, 03\/2026<\/sup><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Das klinische Studienprogramm von MSD in der Schweiz (Stand 01\/2026) (ver\u00f6ffentlicht auf www.clinicaltrials.gov) Zur \u00dcbersicht der schweizweiten Studien, die Teilnehmende suchen, www.humanforschung-schweiz.ch CH-NON-00136, 03\/2026<\/p>\n","protected":false},"author":974,"featured_media":2760,"parent":13045,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"editor_notices":[],"footnotes":""},"class_list":["post-2759","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.9.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Klinische Studien bei MSD Schweiz | msd.ch<\/title>\n<meta name=\"description\" content=\"Die Schweiz ist Teil des globalen klinischen Forschungsprogramms von MSD mit j\u00e4hrlich rund 40 klinischen Studien. Erfahren Sie mehr dar\u00fcber.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.msd.ch\/de\/home\/research\/clinical-trials\/clinical-trials-in-switzerland\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Klinische Studien bei MSD Schweiz\" \/>\n<meta property=\"og:description\" content=\"Die Schweiz ist Teil des weltweiten klinischen Studienprogramms mit j\u00e4hrlich rund 40 klinischen Studien.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.msd.ch\/de\/home\/research\/clinical-trials\/clinical-trials-in-switzerland\/\" \/>\n<meta property=\"og:site_name\" content=\"msd.ch\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-31T19:02:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2021\/07\/clinical-trials-on-track-featured-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1188\" \/>\n\t<meta property=\"og:image:height\" content=\"672\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Klinische Studien bei MSD Schweiz\" \/>\n<meta name=\"twitter:description\" content=\"Die Schweiz ist Teil des weltweiten klinischen Studienprogramms mit j\u00e4hrlich rund 40 klinischen Studien.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2021\/07\/clinical-trials-on-track-featured-image.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.msd.ch\/de\/home\/research\/clinical-trials\/clinical-trials-in-switzerland\/\",\"url\":\"https:\/\/www.msd.ch\/de\/home\/research\/clinical-trials\/clinical-trials-in-switzerland\/\",\"name\":\"Klinische Studien bei MSD Schweiz | msd.ch\",\"isPartOf\":{\"@id\":\"https:\/\/www.msd.ch\/de\/#website\"},\"datePublished\":\"2026-03-31T19:02:02+00:00\",\"dateModified\":\"2026-03-31T19:02:15+00:00\",\"description\":\"Die Schweiz ist Teil des globalen klinischen Forschungsprogramms von MSD mit j\u00e4hrlich rund 40 klinischen Studien. Erfahren Sie mehr dar\u00fcber.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.msd.ch\/de\/home\/research\/clinical-trials\/clinical-trials-in-switzerland\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.msd.ch\/de\/home\/research\/clinical-trials\/clinical-trials-in-switzerland\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.msd.ch\/de\/home\/research\/clinical-trials\/clinical-trials-in-switzerland\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.msd.ch\/de\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Forschung\",\"item\":\"https:\/\/www.msd.ch\/de\/home\/research\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Klinische Studien\",\"item\":\"https:\/\/www.msd.ch\/de\/home\/research\/clinical-trials\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Klinische Studien von MSD in der Schweiz\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.msd.ch\/de\/#website\",\"url\":\"https:\/\/www.msd.ch\/de\/\",\"name\":\"msd.ch\",\"description\":\"MSD erforscht und entwickelt Medikamente und Impfstoffe, die Leben retten und die Gesundheit von Patienten verbessern sollen. In der Schweiz setzen sich 1000 Mitarbeitende in Luzern und Z\u00fcrich daf\u00fcr ein.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.msd.ch\/de\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Klinische Studien bei MSD Schweiz | msd.ch","description":"Die Schweiz ist Teil des globalen klinischen Forschungsprogramms von MSD mit j\u00e4hrlich rund 40 klinischen Studien. Erfahren Sie mehr dar\u00fcber.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.msd.ch\/de\/home\/research\/clinical-trials\/clinical-trials-in-switzerland\/","og_locale":"en_US","og_type":"article","og_title":"Klinische Studien bei MSD Schweiz","og_description":"Die Schweiz ist Teil des weltweiten klinischen Studienprogramms mit j\u00e4hrlich rund 40 klinischen Studien.","og_url":"https:\/\/www.msd.ch\/de\/home\/research\/clinical-trials\/clinical-trials-in-switzerland\/","og_site_name":"msd.ch","article_modified_time":"2026-03-31T19:02:15+00:00","og_image":[{"width":1188,"height":672,"url":"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2021\/07\/clinical-trials-on-track-featured-image.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_title":"Klinische Studien bei MSD Schweiz","twitter_description":"Die Schweiz ist Teil des weltweiten klinischen Studienprogramms mit j\u00e4hrlich rund 40 klinischen Studien.","twitter_image":"https:\/\/www.msd.ch\/de\/wp-content\/uploads\/sites\/88\/2021\/07\/clinical-trials-on-track-featured-image.jpg","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.msd.ch\/de\/home\/research\/clinical-trials\/clinical-trials-in-switzerland\/","url":"https:\/\/www.msd.ch\/de\/home\/research\/clinical-trials\/clinical-trials-in-switzerland\/","name":"Klinische Studien bei MSD Schweiz | msd.ch","isPartOf":{"@id":"https:\/\/www.msd.ch\/de\/#website"},"datePublished":"2026-03-31T19:02:02+00:00","dateModified":"2026-03-31T19:02:15+00:00","description":"Die Schweiz ist Teil des globalen klinischen Forschungsprogramms von MSD mit j\u00e4hrlich rund 40 klinischen Studien. Erfahren Sie mehr dar\u00fcber.","breadcrumb":{"@id":"https:\/\/www.msd.ch\/de\/home\/research\/clinical-trials\/clinical-trials-in-switzerland\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.msd.ch\/de\/home\/research\/clinical-trials\/clinical-trials-in-switzerland\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.msd.ch\/de\/home\/research\/clinical-trials\/clinical-trials-in-switzerland\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.msd.ch\/de\/"},{"@type":"ListItem","position":2,"name":"Forschung","item":"https:\/\/www.msd.ch\/de\/home\/research\/"},{"@type":"ListItem","position":3,"name":"Klinische Studien","item":"https:\/\/www.msd.ch\/de\/home\/research\/clinical-trials\/"},{"@type":"ListItem","position":4,"name":"Klinische Studien von MSD in der Schweiz"}]},{"@type":"WebSite","@id":"https:\/\/www.msd.ch\/de\/#website","url":"https:\/\/www.msd.ch\/de\/","name":"msd.ch","description":"MSD erforscht und entwickelt Medikamente und Impfstoffe, die Leben retten und die Gesundheit von Patienten verbessern sollen. In der Schweiz setzen sich 1000 Mitarbeitende in Luzern und Z\u00fcrich daf\u00fcr ein.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.msd.ch\/de\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/pages\/2759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/users\/974"}],"replies":[{"embeddable":true,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/comments?post=2759"}],"version-history":[{"count":213,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/pages\/2759\/revisions"}],"predecessor-version":[{"id":13980,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/pages\/2759\/revisions\/13980"}],"up":[{"embeddable":true,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/pages\/13045"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/media\/2760"}],"wp:attachment":[{"href":"https:\/\/www.msd.ch\/de\/wp-json\/wp\/v2\/media?parent=2759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}